Mosaiques diagnostics provides highly innovative Clinical Proteomics services for academic institutions and pharmaceutical companies. Mosaiques revolutionary CE-MS technology (capillary electrophoresis coupled to mass spectrometry) helps to diagnose severe diseases at an early development stage.
Precise and reliable detection of diseases in early stages allows prompt initiation of therapy and results in minimizing patients' burden
Explore our offer here
Qualitätskontrolle von Blutprodukten (Quality control of blood products)
Identification of markers for quality and stability of blood products using protein pattern, exemplarily demonstrated by the use of serum eye drops.
Mosaiques’ diagnostics study entitled:
“CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer”
was awarded in 13. Nordkongress Urologie in Hamburg
13 – 15 June 2019
The study presents a CE-MS based urinary test of 19-peptides that enables detection of significant prostate cancer in patients with low levels of PSA (<15ng/ml) with sensitivity of 90% (AUC=0.81), outperforming PSA (AUC = 0.58) and the ERSPC-3/4 risk calculator (AUC = 0.69)
Read the full article here.
Mosaiques Diagnostics nominated for Innovationspreis Niedersachsen 2018.
Read the full article here.
Mosaiques Diagnostics GmbH at the Awards ceremony for the "Innovationspreis Niedersachsen 2018".
"Family’s grief sparks a quest for better bladder cancer cures"
Read the full article here.
Der Erfinder der Proteomanalyse, Prof. Mischak, als „Lecturer of the Year 2018“ vom Belgischen Hypertensie Comité benannt
Führende deutsche Wissenschafts-Institute des „Forum Gesundheitsforschung“ beim BMBF fordern für die dringend benötigte Präzisionsmedizin die klinische Proteomanalyse! Die Wissenschafts-Institute des „Forum Gesundheitsforschung“ sind:
Wissenschaftsrat ● Deutsche Forschungsgemeinschaft ● Helmholtz-Gemeinschaft ● Max-Planck-Gesellschaft ● Leibniz-Gemeinschaft ● Fraunhofer Gesellschaft ● Medizinischer Fakultätentag ● Verband der Universitätsklinika Deutschland ● Deutsche Zentren der Gesundheitsforschung ● Vertreterinnen und Vertreter aus der Wirtschaft
The mosaiques diagnostics & therapeutics AG was established in Hannover (Germany).
The company’s core competence is the early and reliable detection of diseases enabling personalized medicine during therapy and drug development. The company utilizes diagnostic polypeptide patterns (DiaPat) derived from the fast and accurate analysis of proteins and polypeptides in body fluids (e.g. urine, bile and cerebrospinal fluid).
FDA issues letter of support for
urinary peptide-based biomarker
to detect early stage of CKD.
-
Mosaiques featured in Horizon Magazin
-
Mosaiques nominated for Innovationspreis Niedersachsen 2018
-
fünfzehN Jahre NBank & mosaiques Group
-
Clinical Proteomics on the Path Toward Implementation: First Promises Delivered
-
